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The chemokine CXCL13 mediates recruitment of B cells to tumors and is essential for the formation 
of tertiary lymphoid structures (TLSs). TLSs are thought to support antitumor immunity and are 
associated with improved prognosis. However, it remains unknown whether TLSs are formed in 
response to the general inflammatory character of the tumor microenvironment, or rather, are induced 
by (neo)antigen-specific adaptive immunity. We here report on the finding that the transforming 




 tumor-infiltrating T-cell (TIL) subpopulation 
expressed and produced CXCL13. Accordingly, CD8
+
 T cells from peripheral blood activated in the 
presence of TGFβ upregulated CD103 and secreted CXCL13. Conversely, inhibition of TGFβ receptor 






 TILs correlated with B-cell 
recruitment, TLSs, and neoantigen burden in six cohorts of human tumors. Altogether, our findings 
indicated that TGFβ plays a non-canonical role in coordinating immune responses against human 






 TILs in mediating B-cell recruitment 
and TLS formation in human tumors.  
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Immune checkpoint inhibitors (ICIs) targeting programmed death ligand 1 (PD-L1) or its receptor, 
programmed death 1 (PD-1), have elicited unprecedented long-term disease remissions in advanced 
and previously treatment-refractory cancers [1–3]. Unfortunately, only a subset of patients currently 
benefit from treatment. ICIs are more likely to be effective in patients with a pre-existing anti-cancer 
immune response, most notably a CD8
+
 cytotoxic T-cell response against tumor neoantigens [4]. 
Responsive tumors harbor significantly more predicted neoantigens [5,6] and display 
evidence of a coordinated immune response comprising T cells, dendritic cells (DCs), and B cells [7]. 
In diseases that parallel tumor development, such as chronic inflammatory conditions, this 
coordinated infiltration by different immune cell subsets is frequently associated with tertiary lymphoid 
structures (TLSs) – an ectopic form of lymphoid tissue. TLSs exhibit features of regular lymph nodes, 
including high endothelial venules, a T-cell zone with mature DCs, and a germinal center with 
follicular DCs and B cells [8]. Several studies have reported the presence of TLSs in tumors, which 
was generally found to be associated with greater immune control of cancer growth and improved 
prognosis [9,10]. For several malignancies, the combination of TLS presence and high CD8
+
 T-cell 
infiltration was found to associate with superior prognosis, whereas high CD8
+
 T-cell infiltration alone 
associated with poor or moderate prognosis [11,12]. These observations highlight the importance of a 
coordinated immune response, including TLS formation, in anti-cancer immunity.  
To date, the molecular determinants of tumor TLS formation remain incompletely understood. 
Current data suggest that TLS formation results from a complex interplay between DCs, T cells, B 
cells, and supporting stromal cells. Interplay amongst these cells relies on reciprocal cytokine and 
chemokine signaling, including chemokine [C-X-C motif] ligand 13 (CXCL13), receptor activator of 
nuclear factor κ B (ligand)(RANK/RANKL), lymphotoxin αβ (LTαβ), and chemokine (C-C motif) ligand 
21 (CCL21) [13]. A central role for CXCL13 in this process is suggested by the inability of B cells to 
home and accumulate into lymphoid aggregates [14] and generate functional lymphoid tissue [15,16] 
in CXCL13-knockout mice and the observation that CXCL13 alone is sufficient to generate lymphoid 
tissues [17–19]. Nevertheless, a key outstanding question remains whether tumor-associated TLSs 
are formed in response to the general inflammatory character of the tumor microenvironment, or 
rather, are induced by (neo)antigen-specific adaptive immunity. Two studies suggest that a subset of 
on April 8, 2019. © 2019 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 





 tumor-infiltrating lymphocytes (TILs) may link (neo)antigen recognition to 
TLS formation [20,21].   
Here, we report the finding that transforming growth factor beta (TGFβ) receptor signaling 
licensed CD8
+
 T cells to produce and secrete CXCL13 upon concurrent T-cell receptor (TCR) 
stimulation. Induction of CXCL13 was paralleled by upregulation of CD103, a marker for tissue-
resident TILs. Accordingly, bulk and single-cell RNA sequencing identified exclusive expression of 
CXCL13 in human CD103
+




 TILs. In line with these data, the presence of 
CD103
+
 cytotoxic T lymphocytes (CTLs) correlated to B-cell recruitment and TLSs in tumors with a 
high mutational load. This discovery sheds light on how B cells could be recruited to tumors by CTLs, 
identifying a non-canonical role for TGFβ in the orchestration of a coordinated immune response 
against human (neo)antigen-rich tumors. Our findings also identify CD103 and B cells as potential 
biomarkers for ICI in epithelial malignancies. 
 
 
Materials and Methods 
Patients 
Tumor tissue from four patients with stage IIIC high-grade serous ovarian cancer was collected during 
primary cytoreductive surgery, prior to chemotherapy, and from one patient with stage IV high-grade 
serous ovarian cancer during interval debulking upon three cycles of chemotherapy. Written informed 
consent was obtained from all patients. Selection of uterine cancer (UC) patients was described 
previously [22]. Briefly, UC tissue was obtained from patients involved in the PORTEC-1[23] and 
PORTEC-2[24] studies (n=57), the UC series (n=67)
 
from Leiden University Medical Center (LUMC), 
and UC series (n=26)
 
from the University Medical Center Groningen in accordance with local medical 
ethical guidelines [25]. Tumor material was fixed in formalin and embedded in paraffin. Tumor 
material from 119 patients was available for analysis. Mutations in the exonuclease domain of 
polymerase epsilon (POLE-EDM) and microsatellite instability status were known from previous 
studies [25]. Of the tumors available for this study, 42 tumors were POLE wild-type and microsatellite 
stable (MSS), 38 were POLE wild-type with microsatellite instability (MSI), and 39 were POLE-EDM. 
POLE-EDM statuses did not co-occur with microsatellite instability. All cases were of endometrioid 
histology (EEC), and the number of low-grade and high-grade tumors was spread equally over the 
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three molecular groups. Selection of ovarian cancer patients and CD103 staining was reported 
previously [26]. Ethical approval for tumor molecular analysis was granted at LUMC, UMCG, and by 
Oxfordshire Research Ethics Committee B (Approval No. 05\Q1605\66).  
 
Analysis of TCGA mRNA sequencing data  
RSEM normalized mRNA-seq data and clinical data from uterine corpus endometrial carcinoma 
(UCEC), ovarian cancer (OV), breast cancer (BRCA), and lung adenocarcinoma (LUAD) were 
downloaded from firebrowse.org on 13-03-2017 (UCEC) and 14-07-2017(OV, BRCA, LUAD). RSEM 
mRNA sequencing expression data were log2 +1 transformed, and genes with zero reads in all 
samples were removed. POLE-EDM, MSI and MSS cases were identified in the endometrial cancer 
data. The mononucleotide and dinucleotide marker panel analysis status was provided by The Cancer 
Genome Atlas (TCGA), and mutations in the exonuclease domain of POLE were determined 
previously [27]. Heatmaps were constructed in R (version 3.3.1) with packages gplots and ggplots. 









 signatures were derived from the sequencing data (Supplementary Table S1). 


















 groups in MSS UCEC were based on median 
expression of CXCL13 (4.35698) and ITGAE (8.086985). Survival curves were constructed with R 
packages survival (version 2.41-3) and survminer (version 0.4.3). All analyses were performed in R 




To assess the presence of TLSs in UC, we stained for the B cell marker CD20 on whole tissue 
sections. Formalin-fixed, paraffin-embedded (FFPE) slides were de-paraffinized and rehydrated in 
graded ethanol. Antigen retrieval was initiated with a preheated 10 mM citrate buffer (pH=6) and 
endogenous peroxidase activity was blocked by submerging sections in a 0.45% hydrogen peroxide 
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solution. Slides were blocked in PBS containing 1% human serum and 1% BSA. Slides were 
incubated overnight with anti-CD20 (0.63 mg/L; clone L26, cat. number M0755, Dako, Glostrup, 
Denmark) at 4°C. Subsequently, slides were incubated with a ready-to-use peroxidase-labeled 
polymer for 30 minutes (Envision+/HRP anti-mouse, 2 drops, cat. number K4001, Dako, Carpinteria, 
USA). Signal was visualized with 3,3’diaminobenzidin (DAB) solution, and slides were counterstained 
with hematoxylin. Appropriate washing steps with PBS were performed in-between incubation steps. 
Sections were embedded in Eukitt mounting medium (Sigma Aldrich, Steinheim, Germany), and 
slides were scanned on a Hamamatsu digital slide scanner (Hamamatsu photonics, Hamamatsu, 
Japan). The number of CD20
+
 (dense) follicles in each slide was quantified in NDPview2 software by 
two independent observers who were blinded to clinicopathological data. 
Immunohistochemistry for CD8 was performed previously in this cohort [25]. To assess the survival 
effect of CD103 infiltration in mismatch repair proficient (pMMR) cancers, we used a staining for 
CD103 on tissue microarray slides of UC [29]. FFPE slides were prepared as described above and 
incubated with rabbit-anti human CD103 (1 mg/L; anti-E7-integrin, clone ERPR4166(2), cat. number 
Ab129202, Abcam, Cambridge UK), followed by a ready-to-use peroxidase-labeled polymer 
(Envision+/HRP anti-rabbit, cat.no. K4003, Dako, Carpinteria, USA) and Biotin Tyramide working 
solution (TSA kit, Perkin Elmer, Waltham, USA), streptavidin-HRP (TSA kit, Perkin Elmer), and 3,3’-
diaminobenzidin/hematoxylin. Positively stained cells were quantified per core and adjusted for core 
surface. Patients with at least two cores with a minimum of 20% tumor epithelium were included for 




FFPE slide preparation and antigen retrieval were performed as described above. Next, slides were 
incubated overnight at 4°C with primary antibody and subsequently incubated with the appropriate 
secondary antibody for 45 minutes at room temperature (Supplementary Table S2). Specific signal 
was amplified using the TSA Cyanine 5 (Cy5) detection kit (Perkin Elmer, NEL705A001KT, Boston, 
USA) or the TSA Cyanine 3 (Cy3) and Fluorescein detection kit (Perkin Elmer, 753001KT, Waltham, 
USA), according to manufacturer’s protocols. To allow multiple amplifications on the same slide, 
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primary HRP labels were destroyed between incubations by washing with 0.01 M hydrochloric acid for 
10 minutes. Appropriate washing steps with PBS containing 0,.05% Tween20 (Sigma-Aldrich, 
Missouri, USA) were performed during the procedure. For embedding, Prolong Diamond anti-fade 
mounting medium with or without DAPI was used (Invitrogen/Thermo Fisher Scientific, P36962 and 
P36961, Oregon, USA). Finally, slides were scanned at room temperature using the TissueFAXS 
acquisition software and microscope (TissueGnostics, Vienna, Austria) with the following 
specifications: Zeiss EC "Plan-Neofluar" 40x/1.30 Oil, DIC objective, CMOS-color camera PL-B623 
Pixelink (3.1 Megapixels), EXFO Excite 120 PC fluorescence illumination and Chroma ET Dapi 
(49000), Chroma ET CY3 (49004), Chroma ET Cy5 (49006), and Chroma FITC (49011) filter sets. 
Overlay images were produced using Adobe Photoshop software. 
  
mRNA sequencing 
Ovarian tumors from two patients were cut into pieces of <1 mm
3
 and placed in a T75 culture flask 
(Nunc™ EasYFlask™ Cell Culture Flasks, cat. no. 156499, ThermoScientific) with digestion medium, 
consisting of RPMI (Gibco, Paisley, UK), 10% fetal bovine serum (FBS, Gibco, Paisley, UK), 
collagenase type IV (1 mg/mL; Gibco, Grand Island, USA), and recombinant human DNase (12.6 
µg/mL; Pulmozyme,Roche, Woerden, the Netherlands) for overnight digestion at room temperature. 
After digestion, the suspension was strained through a 70 µm filter and washed with PBS. Cells were 
centrifuged over a Ficoll-Paque gradient (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), and 
lymphocytes were isolated from between the two layers. After a wash with PBS cells were pelleted. 
Total cell pellet was suspended in 1mL FBS with 10% dimethylsulfoxide (Merck, Darmstadt, 
Germany), and stored in liquid nitrogen until further use.  
Prior to sequencing, tumor digests were thawed on ice, washed with AIM-V medium (Gibco, Paisley, 
UK) with 5% pooled human serum (PHS, One Lambda, USA) and centrifuged at 1000 x g. The total 
cell pellets were resuspended in AIM-V with 5% PHS, and cells were incubated with CD3-BV421, 
CD4-PerCP-Cy5.5, CD8α-APCeFluor780, CD8β-PEcy7, TCRαβ-APC, CD103-FITC, and CD56-PE 














 single cells were sorted on a Beckman Coulter 
Astrios cytometer directly into 4 µL lysis buffer (2 µL of 0.2% Triton X-100, Sigma-Aldrich, cat. no. 
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T9284) with 5% recombinant RNase inhibitor (Westburg-Clontech, cat. no. 2313A), 1 µL of 10µM 
barcoded oligo dT primer, and 1 µL 4x10 mM dNTP mix in 96-well PCR plates. Each well contained a 
unique indexed Oligo dT primer (custom designed by P. van der Vlies, Supplementary Table S4, 
enabling identification of individual cells after pooled RNA sequencing.  
In addition to single cell wells, small bulk populations of 20 cells were sorted per microplate well. Per 
patient, 40 single CD8
+
 T cells (20 wells CD103
+
, 20 wells CD103
–
) and 20 small bulk 20-cell 
populations (10 wells CD103
+
, 10 wells CD103
–
) were sorted. After sorting, the plate was vortexed 
and spun down briefly, and incubated at 72°C for 3 minutes. After this step the plate was kept cool. 
The transcriptomes were amplified by a modified SMART-Seq2 protocol using SmartScribe reverse 
transcriptase (Westburg-Clontech, CL639537), based on a previously published protocol [30]. In brief, 
custom primers were designed that included a PCR-primer recognition site for pre-PCR, a Unique 
Molecular Identifier (UMI), a cell barcode (see Supplementary Table S4), and a poly T-stretch. Each 
cell (or pool) was tagged with an oligo dT primer, including the UMI and cell barcode. A template 
switching pre-PCR was used t o generate cDNA. Pools are made of single cells or pools with unique  
cell barcodes and 500 pg of the pools was  tagmentated and barcoded using a N7xx index and 
custom P5 hybrid primer: 
(AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAG
T*A*C) according the Illumina Nextera XT DNA sample preparation kit protocol (Illumina, cat. no. FC-
131-1096). The pools were purified using AMPure beads, in a ratio of 0.6:1, to remove primer dimers. 
Presence and size distribution of the obtained PCR product were checked on a PerkinElmer LabChip 
GX high-sensitivity DNA chip. A super pool was created by equimolar pooling (1 nmol/L) of the 
Nextera products, and the samples were sequenced on Illumina NextSeq500 2500 using 50 bp 
paired-end reads, one read for the mRNA transcript, and the other for the cell-barcode. The obtained 
RNA sequencing data were demultiplexed into individual FASTQ files. The obtained single-end reads 
were aligned to human reference genome 37 (GRCh37.p13 (GCA_000001405.14), top-level built) 
using STAR (version 2.5.2).  
RNA-SeQC (version 1.1.8) was then used to assess the quality of single cells. Data were visualized, 
and clear low-quality outliers were identified based on the number of transcripts, uniquely mapped 
reads, mapping rate, expression profiling efficiency and exonic rate, and these were removed from 
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further analysis. All cells that did not meet one of the following criteria were removed: <10000 
transcripts detected, <500000 uniquely mapped reads, <1000 genes detected, a mapping rate of 
<0.5, an expression profiling efficiency of <0.4, or an exonic rate of <0.5 (Supplementary Table S5). 
mRNA expression values for single cells are shown in fragments per kilobase million (FKPM) and 
log2+1 transformed. Differential expression in the 20-cell populations was analyzed with DESeq2 






 T cells. For 
this analysis, expression values for each sample have been obtained using RSEM (version1.3.0, with 
Bowtie 2, version 2.2.5, non-stranded and with the single-cell prior activated to account for drop-out 
genes) and have been computed for the Gencode 19 transcriptome annotation for GRCh37 
(reference index built with –polyA activated). Genes with a Benjamini-Hochberg FDR <0.01 and log2 
fold change >1 were selected for further analysis. Differentially expressed genes were visualized in a 
Volcano plot (DESeq2, version 1.16.1). The accession number for the sequencing data reported in 
this study is GSE127888. 
 
ELISA  
TILs from three high-grade serous ovarian cancer digests were stained and sorted as described for 
































 T cells. Sorted T cells remained unstimulated or were activated either 
with a stimulation cocktail containing phorbol myristate acetate (PMA, 40.5µM) and ionomycin 
(670µM, 500x dilution, Invitrogen, 00-4970-93 Carlsbad USA) or with Dynabeads® (2 µL/1x10
5
 cells, 
T-activator CD3/CD28 beads, 11131D, Gibco, Oslo, Norway and Vilnius, Lithuania).  
Peripheral blood CD8
+
 T cells were isolated from blood of four healthy volunteers (Sanquin, written 
informed consent was obtained) by a Ficoll-Paque gradient followed by magnetic activated cell sorting 
with a CD8
+
 T-cell negative selection kit (purity >90%, MagniSort™ Human CD8 T cell Enrichment Kit, 
cat. no. 8804-6812-74; Thermo Scientific, San Diego, USA). Peripheral blood CD8+ T cells were 
incubated in 100 µL AIM-V medium with or without Dynabeads® (2 µL/1x10
5 
cells) for activation, 
recombinant TFGβ1 (rTGF- β1, 100 ng/mL, Peprotech, USA), TGFβ1 receptor inhibitor (10 µM, 
SB431542, Sigma Aldrich/Merck, Saint Louis, USA), or a combination of these. Similar experiments 
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were performed with the addition of IL2 (100 IU/mL. Novartis Pharmaceuticals, UK). For the dose-
response curve, peripheral blood CD8+ T cells from three healthy donors were incubated with or 
without Dynabeads® (2µL/1x10
5
 cells) for activation and with recombinant TFGβ1 at doses ranging 
from 0 to 100 ng/mL (rTGF β1, Peprotech, USA). All cells were cultured in AIM-V medium with 5% 
pooled human serum (cat.no. A25761, One Lambda, Los Angeles, USA) in 96-well plates containing 
1x10
5 
cells per condition. After 7 days, plates were centrifuged and supernatant was collected for 
ELISA.  
CXCL13 sandwich ELISA experiments were performed according to manufacturer’s protocol (Human 
CXCL13/BLC/BCA-1 DuoSet ELISA DY801, R&D Abingdon, UK or, for the dose-response curve, 
Minneapolis, USA). In brief, Nunc MaxiSorp flat-bottom plates (Invitrogen, Carlsbad, USA) were 
coated with a capture antibody, followed by incubation with cell supernatant. Per condition, 70 µL of 
supernatant was diluted with 40 µL 1% BSA in PBS, after which 100 µL was added to the well. 
Binding of CXCL13 was detected using secondary antibody, streptavidin-HRP and TMB 1-Component 
Microwell Peroxidase Substrate (SureBlue, KPL/SeraCare, Milford, USA). Substrate conversion was 
stopped after 20 minutes with 0.01 M hydrogen chloride. Plates were washed with PBS plus 0.05% 
Tween20 in-between incubations. OD values were obtained using a micro plate reader set to 450 nm 
(BioRad iMark
TM
 Microplate reader). Lastly, the derived CXCL13 concentrations (pg/mL) were 
multiplied by 1.57 to correct for diluting. AIM-V medium only was used as a negative control.  
 
Chemokine arrays  
CD8
+
 T cells were isolated from blood of three healthy donors as described above in the ELISA 
section. Per condition, 5x10
5
 cells were cultured in AIM-V medium with 5% PHS in a 24-well plate. 
Cells were either incubated for 7 days in medium alone, with rTGFβ1 (100 ng/mL, Peprotech, USA), 
with Dynabeads® (2 µL/1x10
5
 cells, T-activator CD3/CD28 beads, 11131D, Gibco, Oslo, Norway and 
Vilnius, Lithuania), or with both rTGFβ1 and Dynabeads®. Samples were centrifuged, and 
supernatants were collected to analyze production of chemokines on chemokine arrays, according to 
manufacturer’s instructions (31 chemokines using the Proteome Profiler Human Chemokine Array Kit, 
ARY017, R&D, Abingdon, UK, and 38 chemokines using the Human Chemokine Antibody Array - 
Membrane, ab169812, Abcam, Huissen, the Netherlands) (Supplementary Table S6). In brief, 
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chemokine receptor-coated membranes were incubated with supernatant overnight at 4°C. Per 
condition, 450 µL of supernatant was diluted with 1050 µL buffer, provided by the supplier, and 1500 
µL was added (R&D), or 1000 µL was added undiluted (Abcam). Captured proteins were visualized 
using chemiluminescent detection reagents, provided by the suppliers. Appropriate washing steps 
using wash buffers provided by the suppliers were performed in-between incubation steps. 
Membranes were imaged on the  BioRad ChemiDoc
TM
 MP Imaging System, and densitometric 
analysis of chemokine spots was performed using the Protein Array Analyzer plugin for Image J [31]. 
 
Statistical analyses 








 T cells sorted from human 
ovarian tumors were determined by DESeq2 for 20 cell-populations. Genes with a Benjamini-
Hochberg FDR <0.01 and log2 fold change >1 were selected for further analysis. Differences in 
FPKM-values of single cells were assessed by a Mann-Whitney U test. Differences in number of 
CD20
+
 follicles on FFPE slides of molecular subgroups of EC were determined by a non-parametric 
Kruskal-Wallis test, followed by Dunn’s post-hoc analysis. We analyzed the TCGA mRNA sequencing 
data and compared differences in gene expression between molecular subgroups of EC with a non-
parametric Kruskal-Wallis test and a post-hoc Dunn’s test. Differences in survival were determined by 
a logrank test. CXCL13 production was analyzed using a Kruskal-Wallis comparison with a post-hoc 
Dunn’s test, or, for the dose-response curve, with a two-way ANOVA followed by a post-hoc 
Bonferroni test. The chemokine arrays were analyzed using a Kruskal-Wallis test with a post-hoc 
Dunn’s test. The survival effect of CD103 in pMMR UC was assessed by Kaplan Meier analysis and 
logrank test by comparing ‘above median CD103 expression’ and ‘equal to or below median CD103 
expression’ (cut-off 16.14) patient groups. Uni- and multivariate analyses were performed by disease-
specific cox regression survival analyses (Enter for univariate and Backward and Forward (both LR 
and conditional) methods for multivariate analyses). All statistical analyses were performed using R 
version 3.4.0 or GraphPad Prism (GraphPad Software Inc., CA, USA). A p-value of <0.05 was used 
as a cut-off for significance.   
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Epithelial CD8+ T cells associate with an activated and exhausted transcriptional signature 
We and others have previously shown that intraepithelial CD103
+





are promising targets for ICI therapy [26,32–34]. To understand the underlying transcriptional 
changes in these two cell populations, we performed mRNA sequencing on single- and 20-cell pools 
of CD8
+
 T cells isolated from human tumors. We chose ovarian cancer as a model tumor because of 









 TILs were defined based on a CD3+/TCRαβ+/CD8αβ+/CD56-
/CD4- phenotype (Fig. 1A). Post hoc t-distributed stochastic neighbor embedding (t-SNE) confirmed 




 CTL populations in these tumors (Supplementary Fig. 
S1A-C). The transcriptome of CD103
+
 CTLs was characterized by an activation and exhaustion 
signature (Supplementary Table S7) with significant upregulation of GZMB (granzyme B), HAVCR2 
(T-cell immunoglobulin and mucin domain 3, TIM3), LAG3 (lymphocyte-activation gene 3), TNFRSF18 
(glucocorticoid-induced TNFR-related protein, GITR), KIR2DL4 (killer cell immunoglobulin-like 
receptor 2DL4), TIGIT (T-cell immunoreceptor with Ig and ITIM domain), and CTLA4 (cytotoxic T-
lymphocyte attenuator 4) in the 20-cell pools (Fig. 1B). CD103
+
 CTLs expressed GNGT2 (G protein 
subunit gamma transducin 2), encoding a G protein gamma family member expressed in lymph nodes 
and spleen that is involved in GTPase activity (Fig. 1B). The expression of these markers is in-line 
with our earlier work demonstrating that the intraepithelial CD103
+
 T cells likely represent CTLs that 
have undergone activation and/or exhaustion [26,32]. By contrast, CD103
–
 CTLs displayed a more 
quiescent phenotype with a high differential expression of the V-set domain–containing T-cell 
activation inhibitor 1 (VTCN1), a known suppressor of T-cell function (Fig. 1B). These cells 
differentially expressed GAGE12H, GAGE12I, and GMPR2 (guanosine monophosphate reductase 2), 
involved in cell energy metabolism (Fig. 1B). Finally, CD103
+
, but not CD103
–
, cells were 
characterized by expression of genes previously associated [35] with exhausted CD8
+





 CTLs differentially express the B-cell recruiting chemokine CXCL13 
In addition to the activated and exhausted gene signature, CD103
+
 CTLs were also characterized by 
significantly upregulated expression of the TLS-inducing CXCL13 (Fig. 1B and 1D; p<0.0001). 
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Although traditionally considered a CD4
+
 follicular helper T-cell (TFH) gene, CXCL13 is also 
expressed in subsets of CD8
+
 TILs from hepatocellular carcinoma, melanoma, breast, and non-small 





 T-cell population that predicted response to ICI therapy [36]. We, therefore, determined 






 populations overlapped phenotypically. 




 cells on the mRNA level, although this did 
not reach statistical significance in the 20-cell pools (Fig. 1B-C). Nevertheless, at the protein level, 




 T cells (Fig. 1E-F), 
although considerable heterogeneity existed between patients with regards to PD-1 expression (Fig. 




 CD8+ single-cell mRNA sequencing data 
revealed that PDCD1 was heterogeneously expressed in CD103
+
 cells but absent in CD103
–
 cells 




 T cells (Fig. 
1G). In line with the above, CXCL13 and PDCD1 transcripts were significantly, although poorly, 
correlated (Fig. 1H). Finally, we assessed whether CD103
+
 TILs secreted CXCL13 protein, using 
CD4
+




 TILs and CD4
+
 TILs 
readily secreted CXCL13 upon ex vivo activation with anti-CD3/anti-CD28-conjugated beads or 
PMA/ionomycin (Fig. 1I). 
 
TGFβ primes cytotoxic CD8
+
 T cells to secrete CXCL13 in vitro  





 TILs. Previously, we and others have demonstrated that induction of CD103 on CD8
+
 T 
cells is dependent on concurrent T-cell receptor (TCR) and transforming growth factor beta (TGFβ) 
receptor 1 (TGFβR1) signaling [26,40]. TGFβ  is a reported inducer of exhaustion-related genes such 





 TILs. Therefore, we hypothesized that TGFβ might stimulate CD8
+
 T cells 
to secrete CXCL13. To investigate this, we activated peripheral blood CD8
+
 T cells from healthy 
donors with anti-CD3/anti-CD28-conjugated beads in the presence or absence of recombinant TGFβ1 
(rTGFβ1) and measured secretion of CXCL13. Resting CD8
+
 T cells did not produce or secrete 
CXCL13 (Fig. 2A), nor did they express CD103 at the cell surface. Activation using anti-CD3/anti-
CD28–conjugated beads induced minimal secretion of CXCL13 (Fig. 2A) and a minor upregulation of 
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CD103 (Fig. 2B). Secretion of CXCL13 and expression of CD103 was inhibited by co-incubation with 
a TGFβR1 inhibitor, suggesting autocrine TGFβ signaling was required for this induction of CXCL13 
(Fig. 2A-B). Accordingly, activation of CD8
+
 T cells in the presence of rTGFβ1 induced significant 
CXCL13 secretion (Fig. 2A) and expression of CD103 on the CD8 T-cell surface (Fig. 2B). Again, 
induction of CXCL13 and CD103 were inhibited by co-incubation with a TGFβR1 inhibitor (Fig. 2A-B). 
Induction of CXCL13 by TGFβ was dose-dependent and induced CXCL13 secretion at 0,1 ng/mL 
rTGFβ1 with a peak at 10 ng/mL rTGFβ1 (Fig. 2C). Because IL2 inhibits the secretion of CXCL13 in 
follicular helper CD4
+
 T cells [42], we also examined whether IL2 impacted CXCL13 secretion by 
CD8
+
 T cells. In contrast to CD4
+
 T cells, induction of CXCL13 in CD8
+
 T cells was not inhibited by IL2 





 cells. Based on our findings, we concluded that TGFβ was sufficient for CXCL13 
induction in activated CD8
+
 T cells.  
 
Next, we determined whether TGFβ also modulates secretion of other chemokines. Analysis of 




 TILs revealed a significant upregulation of 
CCL3, CCL5, and CXCL13 and a trend towards overexpression of CCL3L1, CCL4L2, CCL20, and 
CXCL9 in CD103
+
 TILs (Fig. 2E). Subsequent analysis of 47 chemokines secreted from peripheral 
blood CD8
+
 T cells revealed activation-dependent production of CCL4, CCL5, CXCL9, and CXCL10 
(Fig. 2F-G and Supplementary Fig. S2A-C). As before, significantly higher CXCL13 was secreted 
upon activation of T cells in the presence of rTGFβ1 (Fig. 2H-I). By contrast, rTGFβ1 did not affect the 
induction of other chemokines (Fig. 2I). Taken together, our data indicated that TGFβ was a specific 
inducer of CXCL13 in CD8
+










 CTLs associated with a high mutation load, B-cell infiltration, and TLSs 
CXCL13 is a key driver of B-cell recruitment and TLS formation in cancer and autoimmune diseases 




 TIL population would be involved in 
recruitment of B cells and TLS formation across human tumors. We retrospectively analyzed a cohort 
of 125 (high-grade serous) ovarian tumors for CD103
+
 cells and CD20
+





 cells were detected in most patients, with some CD20
+
 cells forming 
aggregates in close proximity to CD103
+
 cells in the tumor epithelium (Fig. 3A). Indeed, division of 
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patients by high (>26.3), intermediate (8.6-26.3), or low (<8.6) CD103
+
 cell infiltration revealed a 





T cells might also link neoantigen-specific T-cell responses to B cell–driven immune responses. To 
address this, we determined whether tumors with a high neoantigen load and concomitantly high 
CD103+ TIL infiltrate were enriched for B cell– and TLS-associated genes in mRNA sequencing data 
from The Cancer Genome Atlas (TCGA). Specifically, we analyzed uterine cancer (UC) samples 
stratified by neoantigen load. In brief, four distinct molecular subtypes can be distinguished in UC: 
microsatellite stable (MSS), microsatellite unstable (MSI), polymerase epsilon exonuclease domain 
mutated (POLE-EDM) tumors, and p53-mutant tumors. We have previously demonstrated an 
increased number of mutations, predicted neoantigens, and (CD103
+
) T cells in POLE-EDM and MSI 
tumors compared to MSS tumors [25]. In-line with the above, MSS tumors mostly lacked B-cell– and 
TLS-related genes, whereas MSI and POLE-EDM tumors were enriched for these genes (Fig. 3C). To 
confirm these findings, we further analyzed an independent cohort of MSS, MSI, and POLE-EDM 
tumors from UC patients for the presence of CD20
+
 B cells by immunohistochemistry. B cells were 
predominantly observed in large aggregations in the tumor and surrounding stroma (Fig. 3D-E). In-
line with the TCGA data, only 48% (20/42) of MSS tumors were found to have B-cell aggregates, 
whereas 74% (28/38) of MSI and 92% (33/36) of POLE-EDM tumors contained B-cell aggregates 
(Fig. 3D). Quantification per tumor revealed a significant increase in the number of B-cell aggregates 
when comparing MSS to POLE-EDM and MSI to POLE-EDM tumors (Fig. 3D, p<0.001 and p<0.01, 
respectively). To confirm that the observed B-cell aggregates were phenotypically similar to TLSs, we 
performed multi-color immunofluorescence. Indeed, B-cell aggregates showed the typical 
characteristics of lymphoid tissues, as determined by the presence of high endothelial venules 
(HEVs), germinal B-cell centers, and DCs surrounded by a rim of T cells (Fig. 3F).  
 




 CTL genes would associate with TLS 
genes across human epithelial tumors. To assess this, we analyzed TCGA mRNA expression data of 


















, CTL genes across all four tumor types 
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 CTLs promote migration of B cells 
to tumors and the formation of TLSs across tumor types. 
 
CXCL13+CD103+CD8 cells correlate to improved survival irrespective of neoantigen burden 




 CTLs were also correlated with improved survival, we analyzed 
clinical outcomes in two cohorts of uterine cancer patients. We focused on tumors with a low 
neoantigen burden because a high neoantigen load is associated with better survival. First, we 
analyzed TCGA endometrial cancers of the MSS subtype and correlated high CXCL13 and CD103 




 MSS tumors had a significantly improved 




 MSS tumors from TCGA (Supplementary Fig. S3A). To 




 CTLs in neoantigen low tumors, we analyzed FFPE 
tumor tissue of an independent cohort of mismatch repair proficient (pMMR) uterine cancers by 
immunohistochemistry (Supplementary Table S8). We were unable to detect CXCL13 protein 
expression in CD103
+
 CTLs, consistent with our previous finding that almost all CD103
+
 cells express 
CXCL13 on the mRNA level (Fig. 1B, 1D, and 1G), but express and secrete the protein only after re-




 CTL infiltration on clinical 
outcome in this cohort by proxy, using CD103 staining. We observed a significant survival benefit for 
patients with mismatch repair proficient tumors infiltrated by a high number of CD103
+
 cells over 
tumors infiltrated by a low number of CD103
+
 cells (Supplementary Fig. S3B). This effect was 
independent of other clinical variables, as demonstrated by multivariate analysis (Table 1). As such, 




 CTLs are associated with improved clinical outcome, 




In this study we reported on the finding that TGFβ stimulates activated CD8
+
 T cells to produce 
CXCL13, a known inducer of TLSs [17–19]. This production of CXCL13 was paralleled by the 
induction of CD103 on the cell surface of CD8
+




 T cells isolated directly 
from human tumors expressed CXCL13 mRNA and secreted CXCL13 protein upon ex vivo 
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T cell–enriched human tumors from TCGA, and the absolute number of B cells associated with a high 
load of predicted neoantigens in an independent cohort of uterine cancers and a cohort of high-grade 
serous ovarian cancers. Our findings shed light on the link between CD8
+
 T-cell activation and the 
migration of B cells into the tumor. Our data also identified CD103 and B cells as potential biomarkers 
of interest for cancer immunotherapy. 
CXCL13 is generally associated with DCs and TFH [42,48,49]. Nevertheless, single-cell 
sequencing of exhausted, tumor-infiltrating T cells of liver cancer, breast cancer, lung cancer, and 
melanoma does support expression of CXCL13 in TILs [36–38]. We found that TGFβ1, a cytokine 
mostly associated with immune suppression [42,50–52], was essential for the induction of CXCL13. 
Under homeostatic conditions, TGFβ1 is abundantly present in epithelial tissue and controls the 
epithelial localization of resident memory immune subsets, such as the intraepithelial lymphocytes in 
the colon [53]. In epithelial cancers, we suggest that TGFβ1 has a similar role in promoting not only 
recruitment, signaling, and retention of CD8
+
 T cells via CD103 expression [54], but also stimulating 
immunity via attraction of C-X-C chemokine receptor type 5 (CXCR5)
+
 immune cells through CXCL13 
signaling.  
CXCL13 is the key molecular determinant of TLS formation [17–19], ectopic lymphoid 
structures that are thought to enable efficient local priming of T cells by DCs [9]. Hereby, the time-
consuming migration of DCs and T cells to and from lymph nodes may be circumvented, augmenting 
local antitumor immunity. In-line with this, characteristic components of TLSs, such as HEVs and B 
cells, are found to be generally associated with an improved prognosis [10], and plasma B cells in the 
TLSs are thought to enhance antitumor responses by production and subsequent accumulation of 
antitumor antibodies, potentially leading to antibody-dependent cytotoxicity and opsonization [12]. 
Thus, TLSs may orchestrate a joint T- and B-cell response to improve antitumor immunity.  
Because TLSs were more abundant in tumors with a high mutational load, we postulated that 
activated CD103
+
 CTLs were involved in the migration of B cells to tumors via production of CXCL13. 
This is supported by our observations that mutated, CD8
+
 T cell–rich tumors showed higher 
expression of CXCL13 and ITGAE (CD103) and that they presented with significantly higher numbers 
of B cells. In accordance, a higher degree of TCR clonality within CD8
+
 T cells correlates with a higher 
number of TLSs in non-small cell lung cancer [55]. These TLSs may represent an ongoing immune 
response that is insufficient to halt tumor progression at an early time point. It would, therefore, be of 
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great interest to study the induction and formation of TLSs in developing cancer lesions and to 
determine whether CD8
+
 T-cell infiltration precedes TLS formation.  
In-line with previous work [26,32,56], CD103
+
 CTLs from human tumors were also 
characterized by an activation- and exhaustion-related gene expression signature, with differential 
expression of granzymes and well-known immune checkpoint molecules, such as CTLA4. CD103
+
 
CTLs expressed several additional immune checkpoint genes currently under clinical investigation, 





 T cells in lung cancer [36]. The PD-1
T
 subset was transcriptionally distinct 
and characterized by expression of CXCL13. This subset also expressed higher ITGAE, although cell 
surface expression of CD103 was not examined. Nevertheless, our analysis of the gene expression 
















 cells are associated with response to ICI [36].   






 cells and response to ICI is in-line with the 
observation that CD103
+
 CTLs significantly expand upon treatment with nivolumab or pembrolizumab 
(anti–PD-1) in tumor specimens of advanced-stage metastatic melanoma patients [57]. Accordingly, a 
paper by Riaz et al. demonstrates that tumors from patients who responded to nivolumab treatment 
differentially expressed genes such as CXCL13, CTLA4, TIM3, LAG3, PDCD1, GZMB, and tumor 





 CTLs [7]. Pre-treatment, but not on-treatment, CXCL13 was differentially expressed in 
responders vs. non-responders in this study [7]. This may be explained by the low basal CXCL13 
secretion we observed in the exhausted, CD103
+
 CTLs freshly isolated from untreated human tumors. 
In their exhausted state, CTLs might accumulate mRNA encoding several key effector molecules that 
is translated only upon reactivation (e.g. by ICI). Consistent with this, Riaz et al. observed an increase 
in the number of B cell–related genes on-treatment in responding patients [7], perhaps hinting at B-
cell recruitment and the formation of TLSs in these patients upon ICI-mediated release of CXCL13. 
This hypothesis is supported by the observed increases in serum CXCL13 and concomitant depletion 
of CXCR5
+
 B cells from the circulation in patients treated with anti–CTLA-4 and/or anti–PD-1 [58]. Our 





CTL infiltration pre-treatment across malignancies. 
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Several combination immunotherapy regimes that promote CD8
+
 T-cell infiltration and TLS 
formation may also function via CD8
+
 T cell–dependent production of CXCL13. For instance, 
combined therapy with anti-angiogenic and immunotherapeutic agents in mice stimulated the 
transformation of tumor blood vessels into intratumoral HEVs, which subsequently enhanced the 
infiltration and activation of CD8
+
 T cells and the destruction of tumor cells [59,60]. These T cells 
formed structures around HEVs that closely resembled TLSs [59,60]. One of these studies found that 
induction of TLSs was dependent on both CD8
+
 T cells and macrophages [59]. However, the exact 
intratumoral mechanism of action remains unclarified. Because macrophages produce TGFβ in a 
chronically inflamed environment [42], we hypothesize that the macrophages in these studies may 
have generated a TGFβ-enriched environment, thus, leading to the production of CXCL13 chemokine 
by activated T cells and subsequently to the formation of lymphoid structures. TLSs may, therefore, 
reflect an ongoing CD8
+
 T-cell response in cancer. As such, TLSs may be used as a biomarker to 
predict response to ICI, and these structures may be used as a general biomarker for response to 
immunotherapy because TLS were found to identify pancreatic cancer patients who responded to 
therapeutic vaccination [61]. 
Taken together, we demonstrated that TGFβ1 induces co-expression of CXCL13 and CD103 
in CD8
+
 T cells, potentially linking CD8
+
 T-cell activation to B cell migration and TLS formation. Our 
findings provide a perspective on how (neo)antigens could promote the formation of TLSs in human 
tumors. Accordingly, CD103
+
 cells and B cells should be considered as a potential predictive or 
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Table 1. Cox regression survival analysis                
Disease-specific survival - n=189                 
  Univariate   Multivariate 
  HR 95% CI  p-value   HR 95% CI p-value 
Age of diagnosis (cont) 1.022 0.989 1.056 0.197           
Grade of differentiation                   
Good/moderate ref ref ref ref   ref ref ref ref 
Poor/undifferentiated 4.934 2.307 10.550 <0.0001   2.694 1.192 6.091 0.017 
FIGO stage 
    
          
I ref ref ref ref   ref ref ref ref 
II 1.425 0.261 7.780 0.683   1.016 0.184 5.617 0.985 
III 8.117 2.646 24.906 <0.0001   4.403 1.349 14.371 0.014 
IV 22.707 7.218 71.432 <0.0001   15.697 4.762 51.735 <0.0001 
Myometrial invasion 
    
          
No ref ref ref ref           
Yes 3.425 1.568 7.480 0.002           
LVSI 
    
          
No ref ref ref ref           
Yes 5.617 2.650 11.907 <0.0001           
Lymph node metastasis 
    
          
No ref ref ref ref           
Yes 4.620 1.911 11.171 0.001           
No sampling 0.775 0.299 2.011 0.601           
CD103  
    
          
Low ref ref ref ref   ref ref ref ref 
High 0.249 0.107 0.581 0.001   0.273 0.114 0.652 0.003 
FIGO - International Federation of Gynecology and Obstetrics              
CD103 - low is lower than or equal to median expression; high is higher than median expression       
ref - reference                    
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Figure 1. CD103+ CD8+ TILs display a distinct phenotype and gene signature characterized by 
exhaustion genes and CXCL13 expression. 






 T cells according to TCRαβ, CD3, CD56, CD4, 
CD8α, CD8β, and CD103 expression. One exemplary ovarian tumor is depicted. B, Volcano plot of 




 TILs as determined by RNA sequencing, 
annotated by a set of exhaustion and chemokine related genes. Significance was determined as 
Benjamini-Hochberg FDR <0.01 and log2 fold-change >1. C,D, Expression of exhaustion-related 




 subsets (n=20). 
The lines indicate median values+/- IQR. E, Cell surface expression of CD103 and PD-1 in gated 
CD8
+
 TILs from exemplary ovarian tumor digests (n=3) determined by flow cytometry. The red line 







 TIL subsets determined by flow cytometry (n=8). Graphs indicate 
median and IQR. G, Expression of PDCD1 and CXCL13 in single CD103
–
 (n=12) and CD103
+
 TILs 
(n=12). Graphs indicate median and IQR. Significance in (F-G) was determined as Mann-Whitney U 
test *P<0.05, **P<0.01. H, Correlation of PDCD1 and CXCL13 expression in CD103
+
 TILs (n=24). I, 
Secretion of CXCL13 by CD103
+
 TILs and control CD4
+
 TILs after stimulation overnight at 37°C using 
anti-CD3/CD28 T-cell activation beads (2 µL dynabeads per 1x10
5
 cells) or PMA/ionomycin (500x 
dilution according to manufacturer’s instructions), determined by ELISA Mean plus S.E.M. of TILs 
from ovarian tumors (n=3) are depicted. Significance was determined by Kruskal-Wallis comparison 
with a post-hoc Dunn’s test. *P<0.05; ns, not significant. 
 
Figure 2. TGF-β-dependent induction of CXCL13 in CD8+ T cells and CD103+ TIL chemokine 
profile. 
A, Secretion of CXCL13 by sorted peripheral blood CD8
+
 T cells after stimulation for 7 days using 
anti-CD3/CD28 T cell activation beads (2 µL per 1x10
5
 cells), recombinant TGFβ1 (100 ng/mL) and/or 
TGFβ1 receptor inhibitor SB431542 (10 µM), determined by ELISA. Depicted are mean plus S.E.M. of 
CD8+ T cells from 4 donors. Significance was determine using Kruskal-Wallis comparison with a post-
hoc Dunn’s test. *P<0.05. B, Cell surface expression of CD103 on sorted CD8
+
 T cells after 
stimulation using anti-CD3/CD28 T cell activation beads, recombinant TGFβ1 and/or TGFβ1 receptor 
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inhibitor SB431542 as described for (A). One exemplary donor is depicted. C, Secretion of CXCL13 
as determined by ELISA of CD8
+
 T cells after stimulation using anti-CD3/CD28 T cell activation beads 
as described for (A) and/or varying concentrations of recombinant TGFβ1 as depicted on the x-axis. 
Mean plus S.D. from 3 donors is depicted. Significance was determined by a two-way ANOVA 
followed by a post-hoc Bonferroni test. *P<0.05; ****P<0.0001. D, Secretion of CXCL13 by sorted 
peripheral blood CD8
+
 T cells after stimulation using anti-CD3/CD28 T cell activation beads, 
recombinant TGFβ1 and/or TGF-β1 receptor inhibitor SB431542 (as described for (A)) in the 
presence of IL2 (100 IU/mL), determined by ELISA. Depicted are mean plus S.E.M. of CD8
+
 T cells 
from 4 donors. Significance was determine using Kruskal-Wallis comparison with a post-hoc Dunn’s 




 TILs determined by 
differential expression of RNA sequencing of 20-cell pools (n=20). Dashed red line indicates ≥2-fold 
change; dashed blue line indicates ≤0.5-fold change. Error bars indicate fold-change standard error. 
Significance was determined using Benjamini-Hochberg FDR. F, Secretion of chemokines by CD8
+
 T 
cells after 7 days stimulation using anti-CD3/CD28 T cell activation beads (2 µL per 1x10
5
 cells) 
determined by a chemokine array kit. n=3. Shown are Log2 fold changes of the mean compared to 
resting unstimulated CD8
+
 T cells. Dashed red line indicates ≥2-fold change; dashed blue line 
indicates ≤ 0.5-fold change. Error bars indicate S.E.M. G. Exemplary chemokine array data from anti-
CD3/CD28-activated CD8
+
 T cells of one donor depicting chemokines with ≥2-fold and ≤0.5-fold 
change compared to resting CD8
+
 T cells from panel (F). H,I, Secretion of chemokines by CD8
+
 T 
cells after stimulation using anti-CD3/CD28 T cell activation beads and recombinant TGFβ1 (n=4). 
Shown are Log2 fold changes of the mean compared to (H) resting unstimulated CD8
+
 T cells or to (I) 
anti-CD3/CD28-activated CD8
+
 T cells. Dashed red line indicates ≥2-fold change; dashed blue line 
indicates ≤0.5-fold change. Error bars indicate S.E.M. Significance in (F-I) was determine using 
Kruskal-Wallis comparison with a post-hoc Dunn’s test. *P<0.05 **P<0.01 ****P<0.0001. 
 




 T cells in human 
tumors. 




 cells in ovarian cancer. (A) Exemplary 
image of a CD20
+
 aggregate in close proximity to CD103
+
 cells in the tumor epithelium and (B) B-cell 
infiltration in CD103-low, CD103-intermediate, and CD103-high tumors stratified by tertile (n=125). 
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Significance was determine using Kruskal-Wallis comparison with a post-hoc Dunn’s test. *P<0.05 





 follicular helper T cell–associated genes in TCGA data of uterine cancer (UCEC, 
n=546). Tumors were ranked according to molecular subtype and then by CD20 expression. D,E, 
Prevalence and number of B-cell aggregates (D) in MSS, MSI, and POLE-EDM uterine cancers. (E) 
One exemplary image of each subtype is depicted. Significance was determine using Kruskal-Wallis 
comparison with a post-hoc Dunn’s test. **P<0.01 ***P<0.001. F, Immunofluorescent analysis of 
CD20 aggregates in uterine cancer. CD20 aggregate expression of characteristic TLS markers 






 TIL genes correlate with TLS-associated genes across cancer types. 








 cells in 
ovarian (n=307), uterine (n=546), lung (n=517) and breast (n=1100) cancer. Correlation plots depict 
relative correlation of log2+1 transformed mRNA sequencing data from TCGA. 
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